Health Care & Insurance  October 11, 2017

Corden Pharma acquires Hospira Boulder manufacturing plant

BOULDER — Germany-based pharmaceutical manufacturer Corden Pharma International GmbH has agreed to acquire the Hospira Boulder manufacturing plant from New York-based Pfizer Inc.

Financial terms of the deal were not disclosed, but the deal is expected to close in November. Pfizer announced in June last year that it intended to close or sell the Hospira facility.

Hospira Boulder, to be renamed Corden Pharma Boulder, will be managed by Brian McCudden, chief executive of Corden Pharma Colorado Inc., who was responsible for Hospira Boulder during one of his previous assignments as an employee of Hospira.

SPONSORED CONTENT

Solar Operations and Maintenance for Commercial Properties

One key qualification to consider when selecting a solar partner to install your system is whether they have an Operations and Maintenance (O&M) or service department. Since solar is a long-term asset with an expected lifecycle of 30 plus years, ongoing O&M should be considered up front. A trusted O&M partner will maximize your system’s energy output and therefor the return on your investment.

The 100 workers at the Hospira plant will become employees of Corden Pharma, said Abbey Thompson, a spokeswoman for Corden Pharma Colorado.

Corden Pharma will enter into a multiyear supply arrangement with Pfizer, with the expectation that the agreement will help defray costs associated with running the site for the next few years while it adds new client work into the plant, according to a company statement.

The 54,000-square foot site at 4876 Sterling Drive in Boulder is relatively close to Corden Pharma Colorado’s manufacturing plant at 2075 55th St. It is capable of manufacturing APIs — active pharmaceutical ingredients — and other products.

Corden Pharma International is the global pharmaceutical manufacturing and service platform of International Chemical Investors Group, which is based in Luxembourg.

 

BOULDER — Germany-based pharmaceutical manufacturer Corden Pharma International GmbH has agreed to acquire the Hospira Boulder manufacturing plant from New York-based Pfizer Inc.

Financial terms of the deal were not disclosed, but the deal is expected to close in November. Pfizer announced in June last year that it intended to close or sell the Hospira facility.

Hospira Boulder, to be renamed Corden Pharma Boulder, will be managed by Brian McCudden, chief executive of Corden Pharma Colorado Inc., who was responsible for Hospira Boulder during one of his previous assignments as an employee of Hospira.

THIS ARTICLE IS FOR SUBSCRIBERS ONLY

Continue reading for less than $3 per week!

Get a month of award-winning local business news, trends and insights

Access award-winning content today!

Already have a paid subscription?

Sign up for BizWest Daily Alerts